534 related articles for article (PubMed ID: 26152804)
21. Comparison between Immunocytochemistry, FISH and NGS for
Frankel D; Nanni I; Ouafik L; Camilla C; Pellegrino E; Beaufils N; Greillier L; Dutau H; Astoul P; Kaspi E; Roll P
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142468
[TBL] [Abstract][Full Text] [Related]
22. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
23. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
25. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
Frankel D; Kaspi E; Roll P
Methods Mol Biol; 2021; 2279():157-164. PubMed ID: 33683692
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
29. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
30. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
31. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
32. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.
Betz BL; Dixon CA; Weigelin HC; Knoepp SM; Roh MH
Cancer Cytopathol; 2013 Sep; 121(9):489-99. PubMed ID: 23536384
[TBL] [Abstract][Full Text] [Related]
33. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks.
Zito Marino F; Rossi G; Brunelli M; Malzone MG; Liguori G; Bogina G; Morabito A; Rocco G; Franco R; Botti G
Cancer Cytopathol; 2017 May; 125(5):303-312. PubMed ID: 28195686
[TBL] [Abstract][Full Text] [Related]
35. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
36. ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital.
Cao Z; Wu W; Zhang W; Li Z; Gao C; Huang Y; Zhang L
Diagn Cytopathol; 2020 Jun; 48(6):524-530. PubMed ID: 32150350
[TBL] [Abstract][Full Text] [Related]
37. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
38. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
Scarpino S; Rampioni Vinciguerra GL; Di Napoli A; Fochetti F; Uccini S; Iacono D; Marchetti P; Ruco L
Lung Cancer; 2016 Jul; 97():95-8. PubMed ID: 27237034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
